(Q33785074)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24452484%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

title

Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24452484%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24452484%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

author name string

Camilla Dalle Vedove

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24452484%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Giampiero Girolomoni

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24452484%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

publication date

23 January 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24452484%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

published in

Dermatology and therapy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24452484%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24452484%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24452484%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

1-9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24452484%20AND%20SRC:MED&resulttype=core&format=json

IL-17 targeted therapies for psoriasis

6 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065277

Association of cardiovascular and metabolic disease genes with psoriasis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065277

Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065277

Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065277

Psoriasis: rationale for targeting interleukin-17.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065277

TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065277

Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065277

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065277

Emerging role of IL-17 in atherosclerosis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065277

Structure and signalling in the IL-17 receptor family

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065277

From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065277

Interleukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma gondii infection

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065277

Functional Cooperation between Interleukin-17 and Tumor Necrosis Factor-α Is Mediated by CCAAT/Enhancer-binding Protein Family Members

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065277

Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065277

Latitude and psoriasis prevalence.

4 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13555-014-0042-5

Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13555-014-0042-5

Hyperuricemia in patients with chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13555-014-0042-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13555-014-0042-5

Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13555-014-0042-5

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13555-014-0042-5

Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13555-014-0042-5

Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13555-014-0042-5

Which are the antibodies to watch in 2013?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13555-014-0042-5

Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065277

Pharmacogenetics of psoriasis:HLA-Cw6but notLCE3B/3Cdeletion norTNFAIP3polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab

30 October 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13555-014-0042-5

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13555-014-0042-5

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13555-014-0042-5

IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A

21 January 2018

1 reference

12 December 2020

Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab

1 reference

12 December 2020

Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study

1 reference

12 December 2020

Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study

1 reference

12 December 2020

Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells

1 reference

12 December 2020

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study

1 reference

12 December 2020

10.1007/S13555-014-0042-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24452484%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

6 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24452484%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

PubMed publication ID

24452484

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24452484%20AND%20SRC:MED&resulttype=core&format=json